source
- J&J touts promising RIPTAC data with 59% PSA reductions in prostate cancer trialAt the European Society for Medical Oncology (ESMO) 2026 meeting in Madrid, Johnson & Johnson presented early clinical data from its RIPTAC platform, which the company acquired through a $3 billion…
- AstraZeneca highlights broad oncology portfolio at ESMO conferenceAt the European Society for Medical Oncology (ESMO) meeting in Madrid, AstraZeneca used the platform to showcase its cancer research. The company presented data on both established medicines and n…